Becton Dickinson and Co (BDX) FinancialsBDXFinancialBecton Dickinson and Co

Becton Dickinson and Co (BDX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Medication Delivery Solutions, accounting for 23.4% of total sales, equivalent to $1.16B. Other significant revenue streams include Medication Management Solutions and Surgery. Understanding this composition is critical for investors evaluating how BDX navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Becton Dickinson and Co maintains a gross margin of 46.76%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 16.28%, while the net margin is 9.05%. These profitability ratios, combined with a Return on Equity (ROE) of 6.61%, provide a clear picture of how effectively BDX converts its operational activities into shareholder value.

In the context of the broader market, BDX competes directly with industry leaders such as EW and MDLN. With a market capitalization of $49.96B, it holds a significant position in the sector. When comparing efficiency, BDX's gross margin of 46.76% stands against EW's 77.46% and MDLN's 26.52%. Such benchmarking helps identify whether Becton Dickinson and Co is trading at a premium or discount relative to its financial performance.

Becton Dickinson's financial performance shows a gross margin of 46.76% in Q3 2026, indicating solid profitability. The company also generated $1.7 billion in free cash flow year-to-date, a 45% increase from the prior year, which supports future investments and shareholder returns.